Abstract: To provide: a composition for oxygen detection, which has excellent oxygen detection characteristic (ability), and which is safer than conventional compositions for oxygen detection, thereby being able to be sealed in packages containing food, pharmaceutical products or the like without anxiety; and an oxygen detector onto which this composition for oxygen detection is applied or printed. This composition for oxygen detection contains a redox dye, a food dye, a reducing sugar, an edible reduction promoter and an edible humectant in the composition, and enables quick detection of the presence or absence of oxygen by means of color change. Since this composition for oxygen detection is composed only of food, a pharmaceutical product and edible components allowed to be used for the food or pharmaceutical product, this composition for oxygen detection is safe to the human body.

Abstract: To provide a display medium that is discolored in a state of being exposed in the presence of oxygen. This display medium has a discoloration layer on a substrate, the discoloration layer being formed with a redox dye, a food dye, a reducing sugar, an edible reduction promoter, an edible moisturizer, and an oxygen detection composition that contains an edible thickener. The oxygen detection composition that forms the discoloration layer is reversibly discolored in accordance with the presence of oxygen, so that the discoloration layer changes color upon transition from an oxygen-free state to an oxygen-present state. Therefore, when the discoloration layer is formed with a letter, a drawing pattern, a symbol or the like, information relating to a commodity constituted by the letter, drawing pattern, symbol or the like is highlighted by discoloration.

Abstract: To provide: a composition for oxygen detection, which has excellent oxygen detection characteristic (ability), and which is safer than conventional compositions for oxygen detection, thereby being able to be sealed in packages containing food, pharmaceutical products or the like without anxiety; and an oxygen detector onto which this composition for oxygen detection is applied or printed. This composition for oxygen detection contains a redox dye, a food dye, a reducing sugar, an edible reduction promoter and an edible humectant in the composition, and enables quick detection of the presence or absence of oxygen by means of color change. Since this composition for oxygen detection is composed only of food, a pharmaceutical product and edible components allowed to be used for the food or pharmaceutical product, this composition for oxygen detection is safe to the human body.

Abstract: To provide a display medium that is discolored in a state of being exposed in the presence of oxygen. This display medium has a discoloration layer on a substrate, the discoloration layer being formed with a redox dye, a food dye, a reducing sugar, an edible reduction promoter, an edible moisturizer, and an oxygen detection composition that contains an edible thickener. The oxygen detection composition that forms the discoloration layer is reversibly discolored in accordance with the presence of oxygen, so that the discoloration layer changes color upon transition from an oxygen-free state to an oxygen-present state. Therefore, when the discoloration layer is formed with a letter, a drawing pattern, a symbol or the like, information relating to a commodity constituted by the letter, drawing pattern, symbol or the like is highlighted by discoloration.

Abstract: The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.

Abstract: The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.

Abstract: The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, monoamine oxidase inhibitor, a 5-HT2 antagonist or the like), and the like.

Abstract: The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.

Abstract: A method registers access permission from a first device to a second device over a network. When receiving via the network a connection request from the first device of which access permission is not registered, the second device rejects connection from the first device, and shifts to the first mode. In a first mode, the second device detects user's operation on the second device, and judges whether the detected user's operation is an operation regarding viewing of a reproduction signal from the second device. If the user's operation is not the operation regarding viewing, the second device shifts to the second mode for registering access permission. If the user's operation is the operation regarding viewing, the second device does not shift to the second mode.

Abstract: Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosine A2A receptor antagonist to a patient in need thereof, optionally in combination with an anxiolytic(s) other than the adenosine A2A receptor antagonist.

Abstract: A robotic system includes: a detection unit that detects at least one of a voice, light and an image of a content outputted by a content output device; a decision unit that assesses information detected by the detection unit on the basis of reference data so as to assess the content outputted by the content output device; and a control unit that controls a behavior or a state of the robotic system on the basis of the assessment made by the decision unit.

Abstract: The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, monoamine oxidase inhibitor, a 5-HT2 antagonist or the like), and the like.

Abstract: The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, monoamine oxidase inhibitor, a 5-HT2 antagonist or the like), and the like.

Abstract: A network system according to an implementation of the present invention involves: determining whether or not a matching address is found by comparing (i) an apparatus address, of an apparatus connected to an HDMI network, which is obtained via the HDMI network with (ii) an apparatus address, of an apparatus connected to another network, which is obtained via the other network (S44). Here, the matching address represents a match between the apparatuses addresses. When determining that the matching address is found, the implementation of the present invention involves determining that the terminal apparatus having the matching address is connected to a control apparatus via both of the HDMI network and the other network (S46).

Abstract: Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosine A2A receptor antagonist to a patient in need thereof, optionally in combination with an anxiolytic(s) other than the adenosine A2A receptor antagonist.

Abstract: A television set includes: an internal speaker which outputs sound; a memory which holds information; a remote controller receiver which receives an instruction from the outside of the television set; a microcomputer which causes, based on a mode specifying instruction for specifying a sound output mode received by the remote controller receiver, the memory to hold any one of (a) information that indicates a first sound output mode in which sound is outputted from the internal speaker and (b) information that indicates a second sound output mode in which sound is outputted from an external speaker that is a speaker outside the television set; and an HDMI/CEC communication unit which outputs the information that indicates the sound output mode and that is held by the memory, to an amplifier which controls to operate or not operate the speaker outside the television set.

Abstract: Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosine A2A receptor antagonist to a patient in need thereof, optionally in combination with an anxiolytic(s) other than the adenosine A2A receptor antagonist.

Abstract: In a method of registering an access permission from a first device to a second device to the second device over a network, when receiving via the network a connection request from the first device of which access permission is not registered, the second device rejects connection from the first device, and shifts to the first mode. In the first mode, the second device detects user's operation on the second device, and judges whether the detected user's operation is an operation regarding viewing of a reproduction signal from the second device. If the user's operation is not the operation regarding viewing, the second device shifts to the second mode for registering an access permission. If the user's operation is the operation regarding viewing, the second device does not shift to the second mode.

Abstract: Methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof and methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. Also, methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA with an effective amount of one or more adenosine A2A receptor antagonists, optionally with a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.

Abstract: The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, monoamine oxidase inhibitor, a 5-HT2 antagonist or the like), and the like.